13855-78-2

Upstream product

• 126265-24-5 N^G-nitro-L-arginine methyl ester 
• 1119-34-2 L-arginine hydrochloride 
• 2188-18-3 Boc-Arg(NO₂)-OH 
• 74-79-3 L-arginine 
• 157-06-2 D-arginine 
• 627-75-8 D-arginine hydrochloride 

Downstream Products

• 59179-51-0 Cbo-L-Leu-nitro-L-Arg-OH 
• 141968-19-6 N^ω-nitro-D-arginine methyl ester 
• 160347-94-4 Fmoc-D-Arg(NO₂)-OH 
• 2279-08-5 Z-D-Arg(NO₂)-OH 
• 1208130-64-6 N-((S)-1-((S)-1-(hydroxyamino)-5-(3-nitroguanidino)-1-oxopentan-2-ylamino)-1-oxopropan-2-yl)-4-methoxybenzamide 
• 1176197-13-9 (S)-4-bromo-N-(1-(hydroxyamino)-5-(3-nitroguanidino)-1-oxopentan-2-yl)-3-nitrobenzamide 
• 1208130-72-6 (S)-methyl 2-((S)-2-(4-methoxybenzamido)propanamido)-5-(3-nitroguanidino) pentanoate 
• 1176196-87-4 2,4-dichloro-N-(1-(hydroxyamino)-5-(3-nitroguanidino)-1-oxopentan-2-yl)benzamide 
• 1176196-89-6 N-(1-(hydroxyamino)-5-(3-nitroguanidino)-1-oxopentan-2-yl)-4-nitrobenzamide 
• 1176197-12-8 N-(1-(hydroxyamino)-5-(3-nitroguanidino)-1-oxopentan-2-yl)-3-methoxybenzamide 
• 1178872-61-1 methyl 2-(4-bromo-3-nitrobenzamido)-5-(3-nitroguanidino)pentanoate 

Relevant academic research and scientific papers

Inhibition of nitric oxide synthesis by N(G)-nitro-L-arginine methyl ester (L-NAME): Requirement for bioactivation to the free acid, N(G)-nitro-L-arginine

1. The L-arginine derivatives N(G)-nitro-L-arginine (L-NOARG) and N(G)-nitro-L-arginine methyl ester (L-NAME) have been widely used to inhibit constitutive NO synthase (NOS) in different biological systems. This work was carried out to investigate whether L-NAME is a direct inhibitor of NOS or requires preceding hydrolytic bioactivation to L-NOARG for inhibition of the enzyme. 2. A bolus of L-NAME and L-NOARG (0.25 μmol) increased coronary perfusion pressure of rat isolated hearts to the same extent (21 ± 0.8 mmHg; n = 5), but the effect developed more rapidly following addition of L-NOARG than L-NAME (mean half-time: 0.7 vs. 4.2 min). The time-dependent onset of the inhibitory effect of L-NAME was paralleled by the appearance of L-NOARG in the coronary effluent. 3. Freshly dissolved L-NAME was a 50 fold less potent inhibitor of purified brain NOS (mean IC50 = 70 μM) than L-NOARG (IC50 = 1.4 μM), but the apparent inhibitory potency of L-NAME approached that of L-NOARG upon prolonged incubation at neutral or alkaline pH. H.p.l.c. analyses revealed that NOS inhibition by L-NAME closely correlated with hydrolysis of the drug to L-NOARG. 4. Freshly dissolved L-NAME contained 2% of L-NOARG and was hydrolyzed with a half-life of 365 ± 11.2 min in buffer (pH 7.4), 207 ± 1.7 min in human plasma, and 29 ± 2.2 min in whole blood (n = 3. in each case). When L-NAME was preincubated in plasma or buffer, inhibition of NOS was proportional to formation of L-NOARG, but in blood the inhibition was much less than expected from the rates of L-NAME hydrolysis. This was explained by accumulation of L-NOARG in blood cells. 5. These results suggest that L-NAME represents a prodrug lacking NOS inhibitory activity unless it is hydrolyzed to L-NOARG. Bioactivation of L-NAME proceeds at moderate rates in physiological buffers, but is markedly accelerated in tissues such as blood or vascular endothelium.

Direct monitoring of biocatalytic deacetylation of amino acid substrates by1H NMR reveals fine details of substrate specificity

Amino acids are key synthetic building blocks that can be prepared in an enantiopure form by biocatalytic methods. We show that thel-selective ornithine deacetylase ArgE catalyses hydrolysis of a wide-range ofN-acyl-amino acid substrates. This activity was revealed by1H NMR spectroscopy that monitored the appearance of the well resolved signal of the acetate product. Furthermore, the assay was used to probe the subtle structural selectivity of the biocatalyst using a substrate that could adopt different rotameric conformations.

Novel L-arginine derivatives as aminopeptidase N inhibitors: design, chemistry, and pharmacological evaluation

Considering the important roles played in tumor, aminopeptidase N has been an appealing target for anti-tumor drug development. Here, a serial of novel aminopeptidase N inhibitors with L-arginine scaffold were designed, synthesized and evaluated for aminopeptidase N inhibitory activities. The preliminary anti-enzyme activity assay demonstrated that compounds 5e, 5h, 11e, 11g, and 11h showed comparable activities with the positive control bestatin, an approved aminopeptidase N inhibitor. In vitro anti-proliferation assay, compound 5f showed excellent activities against four kinds of tumor cells which overexpress aminopeptidase N. In vivo anti-metastasis assay, compounds 5f and 11g exhibited better activities than bestatin. So 5f and 11g should be lead compounds as novel aminopeptidase N inhibitors for further development.

Design, synthesis and primary activity assay of bi- or tri-peptide analogues with the scaffold l-arginine as amino-peptidase N/CD13 inhibitors

A series of bi- or tri-peptide analogues with the scaffold l-arginine were designed, synthesized and evaluated for their inhibitory activities against amino-peptidase N (APN) and metalloproteinase-2 (MMP-2). The primary activity assay showed that all the compounds exhibited higher inhibitory activities against APN than MMP-2. Within this series, compounds C6 and C7 (IC50 = 4.2 and 4.3 μM) showed comparable APN inhibitory activities with the positive control bestatin (IC50 = 3.8 μM).

Design, synthesis and primary activity evaluation of l-arginine derivatives as amino-peptidase N/CD13 inhibitors

A series of l-arginine derivatives were designed, synthesized and assayed for their activities against amino-peptidase N (APN)/CD13 and metalloproteinase-2 (MMP-2). The results showed that most compounds exhibited high inhibitory activities against APN and low activities against MMP-2. Within this series, two compounds 5q and 5s (IC50 = 5.3 and 5.1 μM) showed similar inhibitory activities compared with bestatin (IC50 = 3.8 μM), which could be used as novel lead compounds for the future APN inhibitors development as anticancer agents.